Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Gavin, James R., III
Davies, Melanie J.
Davies, Michael
Vija-Purkar, Ujjwala
Alba, Maria
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1095-P
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [31] The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vijapurkar, Ujjwala
    Alba, Maria
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1693 - 1702
  • [32] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [33] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [34] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [35] IS CANAGLIFLOZIN COST-EFFECTIVE COMPARED TO SITAGLIPTIN ACROSS MULTIPLE LINES OF TYPE 2 DIABETES MELLITUS (T2DM) THERAPY IN IRELAND?
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
  • [36] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [37] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [38] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [39] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [40] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
12345